Visits, assessments, and numbers of participants are tabulated.
Models are adjusted for age, square of age, sex, center (North Carolina, Minnesota, and Maryland for whites; North Carolina and Mississippi for African Americans), educational level (<high school; high school, General Educational Development Test, or vocational school; or college, graduate school, or professional school), body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; <25, 25 to <30, or ≥30), diabetes mellitus, alcohol consumption (never, former, or current), smoking status (never, former, or current), apolipoprotein E (APOE) ε4 genotype (0, 1, or 2 alleles), history of stroke, time as a linear spline with knot at 6 years, age by time spline terms, square of age by time spline terms, sex by time spline terms, center by time spline terms, education by time spline terms, BMI by time spline terms, diabetes mellitus by time spline terms, smoking status by time spline terms, and APOE ε4 genotype by time spline terms. Systolic blood pressure categories are defined as less than 110, 110 to less than 120 (reference group; second data marker), 120 to less than 140, 140 to less than 160, and 160 or more mm Hg. Data points are shown at the midpoint of the categories for the 110 to 120–, 120 to 140–, and 140 to 160–mm Hg groups (115, 130, and 150 mm Hg, respectively) but at the median values for the 2 extreme groups (<110 and ≥160 mm Hg) because of the large range of values seen in each of these groups. A, Global z score. B, Delayed Word Recall Test (DWRT) z score. C, Digit Symbol Substitution Test (DSST) z score. D, Word Fluency Test (WFT) z score. Data markers indicate categorical β values; lines, linear fit; and error bars, categorical 95% CIs.
eMethods 1. Methods for Inverse Probability of Attrition Weighting (IPAW) Models
eMethods 2. Methods for Expanded Measurement
eTable 1. Ten Logistic Regression Models for Inverse Probability of Attrition Weighting (IPAW)
eTable 2. Participant Characteristics by ARIC Visit 5 Attendance Status, Visit 2 (1990-1992)
eTable 3. Additional Adjusted 20-Year Cognitive Change (95% Confidence Intervals) Associated With ARIC Visit 2 (1990-1992) Blood Pressure Categories, Including Use of Medications
eTable 4. Inverse Probability of Attrition (IPAW)-Weighted Results: Additional Adjusted 20-Year Cognitive Change (95% Confidence Intervals) Associated With ARIC Visit 2 (1990-1992) Blood Pressure Categories
eFigure 1. Systolic Blood Pressure With 20-Year Cognitive Change Among African Americans
eFigure 2. Diastolic Blood Pressure With 20-Year Cognitive Change Among Whites
eFigure 3. Diastolic Blood Pressure With 20-Year Cognitive Change Among African Americans
Customize your JAMA Network experience by selecting one or more topics from the list below.
Gottesman RF, Schneider ALC, Albert M, et al. Midlife Hypertension and 20-Year Cognitive Change: The Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurol. 2014;71(10):1218–1227. doi:10.1001/jamaneurol.2014.1646
Hypertension is a treatable potential cause of cognitive decline and dementia, but its greatest influence on cognition may occur in middle age.
To evaluate the association between midlife (48-67 years of age) hypertension and the 20-year change in cognitive performance.
Design, Setting, and Participants
The Atherosclerosis Risk in Communities cohort (1990-1992 through 2011-2013) underwent evaluation at field centers in Washington County, Maryland, Forsyth County, North Carolina, Jackson, Mississippi, and the Minneapolis, Minnesota, suburbs. Of 13 476 African American and white participants with baseline cognitive data, 58.0% of living participants completed the 20-year cognitive follow-up.
Hypertension, prehypertension, or normal blood pressure (BP) at visit 2 (1990-1992) constituted the primary exposure. Systolic BP at visit 2 or 5 (2011-2013) and indication for treatment at visit 2 based on the Eighth Joint National Committee (JNC-8) hypertension guidelines constituted the secondary exposures.
Main Outcomes and Measures
Prespecified outcomes included the 20-year change in scores on the Delayed Word Recall Test, Digit Symbol Substitution Test, and Word Fluency Test and in global cognition.
During 20 years, baseline hypertension was associated with an additional decline of 0.056 global z score points (95% CI, −0.100 to −0.012) and prehypertension was associated nonsignificantly with 0.040 more global z score points of decline (95% CI, −0.085 to 0.005) compared with normal BP. Individuals with hypertension who used antihypertensives had less decline during the 20 years than untreated individuals with hypertension (−0.050 [95% CI, −0.003 to −0.097] vs −0.079 [95% CI, −0.156 to −0.002] global z score points). Having a JNC-8–specified indication for initiating antihypertensive treatment at baseline was associated with a greater 20-year decline (−0.044 [95% CI, −0.085 to −0.003] global z score points) than not having an indication. We observed effect modification by race for the continuous systolic BP analyses (P = .01), with each 20–mm Hg increment at baseline associated with an additional decline of 0.048 (95% CI, −0.074 to −0.022) points in global cognitive z score in whites but not in African Americans (decline, −0.020 [95% CI, −0.026 to 0.066] points). Systolic BP at the end of follow-up was not associated with the preceding 20 years of cognitive change in either group. Methods to account for bias owing to attrition strengthened the magnitude of some associations.
Conclusions and Relevance
Midlife hypertension and elevated midlife but not late-life systolic BP was associated with more cognitive decline during the 20 years of the study. Greater decline is found with higher midlife BP in whites than in African Americans.
Quiz Ref IDAccumulating evidence suggests that hypertension is an important risk factor for cognitive change and dementia. Midlife (45-55 years of age) hypertension may be a stronger risk factor than late-life hypertension, as demonstrated in the Honolulu-Asia Aging Study (midlife blood pressure [BP] was associated with dementia1,2 and late-life cognitive function3) and in a Finnish cohort (for dementia4 and cognitive performance5). In the Atherosclerosis Risk in Communities (ARIC) Study, hypertension was more strongly associated with hospitalizations with a discharge code for dementia when defined in midlife vs late life.6 Other studies7-14 showed hypertension, especially in midlife, predicted cognitive decline in certain cognitive domains, but these studies had a short follow-up, examined a primarily white population, did not address the role of antihypertensives, or did not address attrition.
The ARIC Study is uniquely situated to explore the effects of hypertension (independent of confounders, such as educational level and other vascular risk factors) by evaluating change on the results of 3 cognitive tests completed at several points. Quiz Ref IDThese tests represent domains usually affected by vascular processes (psychomotor speed and executive function) and by Alzheimer neurodegeneration (memory). Identifying midlife hypertension as an important risk factor for cognitive decline yields a potential treatable target, with the recognition that treatment might need to be implemented for decades. Herein, we evaluate the relationship of midlife hypertension with 20-year cognitive change in the ARIC Study, with particular attention to low systolic BP (SBP).
We recruited ARIC participants aged 45 to 64 years (n = 15 792) from November 24, 1986, through March 29, 1990, by probability sampling15 from the following 4 US communities: Washington County, Maryland; Forsyth County, North Carolina; the Minneapolis, Minnesota, suburbs; and Jackson, Mississippi. Participants were examined 5 times (Figure 1) and contacted by telephone annually. The study was approved by each field center’s institutional review board, and all participants provided written informed consent.
Of the 14 348 participants who attended ARIC visit 2 (the baseline cognitive assessment [1990-1992]), we excluded those not identified as African American or white (n = 42), the few African Americans living in Washington County or Minneapolis (n = 49), and participants missing baseline cognitive data (n = 217), BP data (n = 1), or covariates included in regression models (n = 563). After exclusions, 13 476 participants remained.
The Delayed Word Recall Test (DWRT),16 Digit Symbol Substitution Test (DSST),17 and Word Fluency test (WFT)18 were administered at visit 2 (1990-1992) and visit 4 (1996-1998) and the ARIC Neurocognitive Study at visit 5 (2011-2013) in a quiet room by trained examiners using standardized protocols. Recordings were reviewed for quality control.
The DWRT evaluates verbal learning and short-term memory. Participants learn 10 nouns, use them in sentences, and, after 5 minutes, are asked to recall them. The score is the number of nouns recalled (maximum of 10).16 In a normative healthy sample of similarly aged ARIC participants, mean DWRT scores range from 5.2 to 6.7 depending on educational level and race group.19 The DSST evaluates executive function and processing speed. Participants use a key to write symbols corresponding to numbers in 90 seconds. The score, ranging from 0 to 93, is the number of correctly written symbols.17 The ARIC normative means range from 20.3 to 48.2.19 The WFT evaluates executive function and expressive language. Participants generate as many words as possible within 60 seconds starting with F, A, and S, with 1 trial per letter. The total score is the sum of all correct words generated,20 with ARIC normative means ranging from 19.4 to 39.5.19
We generated z scores for each cognitive test score per visit, standardized using the visit 2 mean (SD). We calculated mean test z scores to create global cognition z scores, which we standardized using the visit 2 global z mean (SD).
Covariates and their interactions with time were included in multivariable models as potential confounders. From visit 1, age, sex, race, and educational level (<high school; high school, General Educational Development Test, or vocational school; or at least some college) were self-reported; race was further classified by combining race and study center. At visit 2, body mass index (calculated as weight in kilograms divided by height in meters squared) was measured (<25, 25 to <30, or ≥30), with diabetes mellitus defined as self-reported history of a physician’s diagnosis, use of diabetes medications, fasting blood glucose level of at least 126 mg/dL, or nonfasting glucose level of at least 200 mg/dL (to convert glucose levels to millimoles per liter, multiply by 0.0555). At visit 2, history of alcohol use and smoking were self-reported (current, former, or never); apolipoprotein E ε4 was genotyped (0, 1, or 2 alleles); and prevalent stroke was based on self-reported history before visit 1 or adjudicated stroke follow-up.
We measured SBP and diastolic BP (DBP) using a random zero sphygmomanometer, with 5 minutes of rest before each measurement. The mean of 2 measurements was used as the BP for each visit. Antihypertensive status was recorded (yes or no).
Blood pressure was categorized as normal (SBP of <120 mm Hg, DBP of <80 mm Hg, and no antihypertensive use), prehypertension (SBP of 120-139 mm Hg or DBP of 80-89 mm Hg), or hypertension (SBP of ≥140 mm Hg, DBP of ≥90 mm Hg, or antihypertensive use).21,22 In a secondary analysis, we divided hypertension based on medication use status. We also undertook continuous and categorical SBP and DBP analyses.
An additional analysis categorized all individuals by whether or not treatment would be recommended, defined at visit 2 (when the mean age was 57 years) based on the Eighth Joint National Committee (JNC-8) hypertension guidelines.23Treatment not indicated defined participants without diabetes mellitus and without chronic kidney disease (estimated glomerular filtration rate calculated using the Chronic Kidney Disease Epidemiology Collaboration equation24 of <60 mL/min/1.73 m2) who were 60 years or older with SBP of less than 150 mm Hg and DBP of less than 90 mm Hg or younger than 60 years with SBP of less than 140 mm Hg and DBP of less than 90 mm Hg and who were not using antihypertensives. Indication for treatment defined all participants 60 years or older with SBP of at least 150 mm Hg or DBP of at least 90 mm Hg or younger than 60 years with SBP of at least 140 mm Hg or DBP of at least 90 mm Hg and not using any antihypertensives or all participants with diabetes mellitus or chronic kidney disease (any age) and SBP of at least 140 mm Hg or DBP of at least 90 mm Hg.
Statistical analysis was performed using commercially available software (SAS, version 9.3 [SAS Institute Inc] and STATA, version 13.0 [StataCorp]). A P value of less than .05 was significant, and tests were 2 sided. Linear regression models fit with generalized estimating equations were used to evaluate associations with cognitive performance trajectories using robust variance and an unstructured correlation matrix. Models included adjustment for visit 2 age, age squared, sex, center or a combined race-center variable, education, body mass index, diabetes mellitus, alcohol consumption, smoking status, apolipoprotein E ε4 genotype, and stroke history. Linear spline terms represented time since baseline (knot at 6 years, corresponding to the visits 2-4 interval). We included interaction terms for each covariate with each time spline term except alcohol by time and stroke by time spline (nonsignificant). Based on the interactions of hypertension (or SBP) by time, we calculated the additional 20-year decline associated with each hypertension definition. We found a significant effect modification (P = .01 for interaction) by race for the continuous SBP models, so for SBP we report only race-stratified models. Categorical models did not show race interactions, so for these we present race-combined and race-stratified results. Model diagnostics confirmed adequate model fit. All participants with baseline cognitive testing contributed data to the generalized estimating equation analysis. In a sensitivity analysis, we omitted all cognitive test scores after an adjudicated stroke.
To account for death and dropout, we used the inverse probability of attrition weighting (IPAW) model (eMethods 1 and eTable 1 in the Supplement).25 The IPAW model weighted study participants by the inverse of the probability that they will die or drop out, estimated using logistic regression models, to compensate for underrepresentation of persons with characteristics associated with death or dropout. Individual probabilities are calculated from separate logistic models (eMethods 1 and eTable 1 in the Supplement) using information from visits and annual telephone calls. Weights are calculated as the inverse of the product of these probabilities, stabilized,26 and applied to our generalized estimating equation models.
We also account for informative attrition by assigning cognitive scores to persons missing cognitive data but who had hospitalizations with discharge codes for dementia. A previous report27 found strong associations of these cases with hypertension6 and prior low cognitive performance. Participants without hospitalizations and with dementia codes had nearly identical scores at visits 2 and 4, but those participants hospitalized with dementia about 2 years after visit 4 had z scores 1.33 units lower than at visit 227; using this value, we corrected scores otherwise expected for all individuals hospitalized with dementia discharge codes but who did not attend subsequent visits (eMethods 2 in the Supplement).
A total of 13 476 participants contributed data to this analysis, of whom 3229 were African American. Quiz Ref IDCompared with participants with normal BP (Table 1), those with hypertension were older, were more likely to have diabetes mellitus and stroke, and had lower educational levels and baseline cognitive scores. Individuals with baseline hypertension were twice as likely to die before visit 5 than individuals without hypertension, and 53.9% of individuals with SBP of at least 160 mm Hg at visit 2 died before visit 5 (58.6% in African Americans). Maximum follow-up was 23.5 years; of the 80.8% of participants with at least 1 visit beyond visit 2, the median follow-up time was 19.1 (interquartile range, 6.0-20.8) years. Of the original visit 2 ARIC cohort, participants completing 20-year follow-up were younger and healthier and had higher cognitive performance compared with those who died before visit 5 and those who were alive but did not attend visit 5 (eTable 2 in the Supplement).
Hypertension vs no hypertension was associated with steeper 20-year cognitive decline by 0.056 z score units for global cognition (Table 2). Similar associations were observed for the DSST and WFT. Prehypertension was also significantly associated with DSST decline. The amount of decline in the global cognitive z score during 20 years observed for individuals with prehypertension was 4.8% greater, and for those with hypertension, 6.5% greater, than in individuals with normal BP. An average ARIC participant with normal BP at baseline had a decline of 0.840 global cognitive z score points during 20 years compared with 0.880 global z score points for participants with prehypertension and 0.896 global z score points for participants with hypertension. On the DSST, hypertension was associated with 11.206 (95% CI, 10.831-11.580) fewer symbols during 20 years compared with only 10.100 (95% CI, 9.766-10.433) fewer symbols for normal BP.
Individuals with hypertension who used medications had a nearly identical mean SBP (at visit 2) as those with prehypertension (eTable 3 in the Supplement). Their 20-year decline (−0.050 [95% CI, −0.003 to −0.097]) was intermediate between that of the prehypertensive group (−0.040 [95% CI, −0.085 to 0.005]) and the hypertensive group who did not use medications (−0.079 [95% CI, −0.156 to −0.002]). The latter group had the steepest decline, especially in white participants. Untreated hypertension in African Americans was significantly associated with decline on the DSST.
Omitting cognitive test scores after a stroke resulted in 359 fewer scores. Associations of prehypertension and hypertension with cognitive change were similar to those in the primary analysis.
Individuals with an indication for antihypertensive treatment based on the 2014 JNC-8 recommendations (Table 3)23 had a greater 20-year cognitive decline than individuals without an indication for treatment. Effect sizes were slightly lower than those for participants with hypertension (Table 2), but the comparison is difficult because very few individuals (n = 189) underwent reclassification with the JNC-8 criteria.
Baseline continuous SBP values were significantly associated with decline in white (Figure 2; a decline of 0.048 more global cognitive z points per 20–mm Hg SBP increment [95% CI, −0.074 to −0.022]) but not African American (eFigure 1 in the Supplement; a decline of 0.020 fewer points [95% CI, −0.026 to 0.066]) participants. Visit 5 SBP, however, was not associated with the prior 20-year cognitive change in either race; the coefficient for each 20–mm Hg increment was −0.020 global cognitive z points (P = .09) in white and −0.028 global cognitive z points in African Americans (P = .21). We found no evidence of a J-shaped association, noting lesser, not greater, amounts of decline at the lowest SBP category at visits 2 and 5. Blood pressures at visit 5, when participants were 20 years older, were higher than at visit 2. Associations of DBP with cognitive change were similar to those for SBP (eFigures 2 and 3 in the Supplement).
The magnitude of the effect of categorized hypertension was increased (steeper cognitive decline of 0.091 global cognitive z score units during 20 years compared with 0.056 in the primary analysis) after accounting for dropout and death using IPAW methods (eTable 4 in the Supplement). After IPAW modeling, the DSST association with hypertension in African Americans reached statistical significance and was of similar magnitude to that in whites (−0.084 and −0.105, respectively; eTable 4 in the Supplement).
Adding IPAW to the models evaluating the treatment indication for hypertension increased the effect estimate for the overall sample (−0.084 for the global cognitive z score vs −0.044) and in whites (−0.056) but not in African Americans (−0.100).
Using expanded measurement for missing scores for individuals with hospitalizations with dementia (eMethods 2 in the Supplement) led to stronger coefficients for hypertension (−0.086 global cognitive z units for 20-year change overall compared with −0.056 without this expanded measurement), with similar strengthening of results for prehypertension and by race.
In our study of 13 476 individuals followed up for as long as 23 years with rigorous BP and covariate measurement and standardized cognitive assessment, hypertension in midlife was independently associated with a steeper decline in cognitive performance. As hypothesized, hypertension was most consistently associated with the DSST score, the test reflecting domains most typically affected by vascular disease.28 Although other studies have suggested that lower BP might lead to hypoperfusion and thus worse cognitive outcomes in older persons,29,30 we did not find support for this suggestion based on midlife BP. Quiz Ref IDIn contrast to studies supporting a J-shaped curve from midlife BP (with worse outcomes at very low BP for cognition,31 cardiovascular disease,32 stroke,33 and brain white matter hyperintensities [in older persons]34), we found a nearly continuous effect of midlife SBP, with steeper cognitive decline as BP increased in whites only.
The lack of an association between current (late-life) BP and prior cognitive change in our study in combination with other clinical trials failing to show improvement in cognitive function among elderly individuals treated to lower BP targets35 supports the view that, at the population level, higher BP in later life may be less detrimental, perhaps because hypertension at a later age reflects new conversion36 or because of reverse causation (lower BP in individuals who are already experiencing neurodegeneration).37 Evidence considered in the recently published JNC-8 guidelines for hypertension23 led to a recommendation for less tight control in persons older than 60 years. Our results suggest that those participants with an indication for treatment under these guidelines have more decline than individuals without an indication for treatment. However, results were very similar to those seen for the classically defined hypertension categories, likely due to significant overlap of the persons categorized into the JNC-7 hypertension category and the JNC-8 indication for treatment category.
Evaluation of cognitive change instead of dementia or cognitive performance at a single point allows for a reduction of the influence of confounding factors, such as cultural factors or inherited cognitive ability. The utility of this approach is demonstrated by previous findings in the ARIC Study that educational level, although strongly associated with cognitive performance at any single visit, is not an important predictor of cognitive change.38,39
The additional effect of hypertension beyond that of aging alone appears to be relatively modest (6.5% more decline after 20 years). A primary limitation of our study that may account for the relatively modest effect sizes involves the attrition observed in individuals not only with the worst cognition but also the highest baseline BP. However, as shown by our sensitivity analyses, our estimates of the BP–cognitive change relationship are likely to be conservative. The IPAW modeling increased the estimate of the hypertension-associated change in 20-year race-combined global cognitive z scores by almost 70% from −0.056 to −0.091. Furthermore, consideration of scores for patients hospitalized with dementia also increased our estimated hypertension-associated declines; these effects may be supplementary to the effects of adjusting for attrition. We believe the bias due to attrition is a primary reason for the relative lack of an observed association between hypertension and cognitive decline in African American participants, with the smaller sample size further reducing power. Proportionately more African American than white participants died before visit 5 across all hypertension strata, and the highest BPs at baseline associated with the highest mortality rates were seen most frequently in African Americans. Systolic BP also increases stroke risk 3-fold more for African Americans than for whites,40 possibly further increasing disproportionate attrition. These patterns could lead to dilution of an association and explain our lack of an association in African Americans. Treatment decisions are also likely to affect attrition; individuals with better BP management in midlife may be less likely to die or to experience cognitive impairment, and thus less attrition would be noted in these individuals. In addition, many vascular risk factors co-occur, and hypertension, in combination with other vascular risk factors such as diabetes mellitus or smoking, may have additive effects on cognitive change and on attrition.
In the Honolulu-Asia Aging Study,41 use of β-blockers was associated with a lower risk for cognitive impairment independent of BP level; data from this study were also used to attribute 27% of dementia cases among persons not taking antihypertensives in midlife to SBP elevations.42 Our results also suggest that medication reduces the decline attributable to hypertension, but analysis of antihypertensive treatment is vulnerable to healthy user and indication biases. Users may be more adherent, follow physicians’ orders, or have better access to care and healthier habits. However, antihypertensives are given to people with higher BPs, possibly decreasing any observed antihypertensive-induced reduction in cognitive decline, but we see less decline in people using antihypertensives despite this decrease. Antihypertensive use also changes over time, with initiation of treatment in later years in many initially untreated participants.
Although evidence of a definitive benefit of antihypertensive treatment would require a randomized clinical trial (such as the ongoing Systolic Blood Pressure Intervention Trial–Memory and Cognition in Decreased Hypertension [SPRINT-MIND]), existing clinical trials may not be of long enough duration to demonstrate a benefit. Thus, studies like the ARIC Neurocognitive Study are necessary to observe effects occurring during decades of exposure. Although we note a relatively modest additional decline associated with hypertension, lower cognitive performance increases the risk for future dementia, and a shift in the distribution of cognitive scores, even to this degree, is enough to increase the public health burden of hypertension and prehypertension significantly. Initiating treatment in late life might be too late to prevent this important shift. Epidemiological data, including our own study, support midlife BP as a more important predictor of—and possibly target for prevention of— late-life cognitive function than is later-life BP.
Quiz Ref IDMidlife hypertension, by several definitions, and elevated midlife but not late-life SBP were associated with more cognitive decline during the 20-year ARIC Study. Greater linear decline is found with higher midlife BP in white than in African-American participants.
Accepted for Publication: May 13, 2014.
Corresponding Author: Rebecca F. Gottesman, MD, PhD, Department of Neurology, Johns Hopkins University School of Medicine, Phipps 446D, 600 N Wolfe St, Baltimore, MD 21287 (firstname.lastname@example.org).
Published Online: August 4, 2014. doi:10.1001/jamaneurol.2014.1646.
Author Contributions: Dr Gottesman had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Gottesman, Schneider, Bandeen-Roche, Coresh, Sharrett, Mosley.
Acquisition, analysis, or interpretation of data: Gottesman, Schneider, Albert, Alonso, Bandeen-Roche, Coker, Knopman, Power, Rawlings, Sharrett, Wruck, Mosley.
Drafting of the manuscript: Gottesman.
Critical revision of the manuscript for important intellectual content: Schneider, Albert, Alonso, Bandeen-Roche, Coker, Coresh, Knopman, Power, Rawlings, Sharrett, Wruck, Mosley.
Statistical analysis: Gottesman, Schneider, Bandeen-Roche, Power, Rawlings, Sharrett, Wruck.
Obtained funding: Coker, Coresh, Mosley.
Administrative, technical, or material support: Coker.
Study supervision: Bandeen-Roche.
Conflict of Interest Disclosures: Dr Knopman serves as deputy editor for Neurology; serves on a data safety monitoring board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer’s Disease Treatment Unit; served on a data safety monitoring board for Lilly Pharmaceuticals (completed 2012); served as a consultant to Tau RX (completed 2012); was an investigator in clinical trials sponsored by Baxter and Elan Pharmaceuticals in the past 2 years (completed 2012); and receives research support from the National Institutes of Health (NIH). No other disclosures were reported.
Funding/Support: The ARIC Study is part of a collaborative study supported by contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C from the National Heart, Lung, and Blood Institute (NHLBI). Neurocognitive data collection was supported by contracts U01 HL096812, HL096814, HL096899, HL 096902, and HL 096917 from the NHLBI and the National Institute of Neurological Disorders and Stroke, and previous magnetic resonance imaging examinations of the brain were supported by contract R01-HL70825 from the NHLBI. This study was also supported by contract T32HL007024 from the NHLBI, NIH (Dr Schneider and Ms Rawlings) and by contract T32AG027668 from the National Institute on Aging, NIH (Dr Power).
Role of Sponsor: The funding sources had no role in the design and conduct of the study other than membership by program officers on the study steering committee; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Information: Members of the ARIC Neurocognitive Study (NCS) Steering Committee include Thomas H. Mosley, PhD (chair), Josef Coresh, MD, PhD (cochair), Marilyn Albert, PhD, Alvaro Alonso, MD, PhD, Christie Ballantyne, MD, Eric Boerwinkle, PhD, David Couper, PhD, Gerardo Heiss, MD, PhD, Clifford Jack, MD, Barbara Klein, MD, MPH, Ronald Klein, MD, MPH, David Knopman, MD, Natalie Kurinij, PhD (National Eye Institute project officer), Claudia Moy, PhD (National Institute of Neurological and Communicative Diseases and Stroke project officer), and Jacqueline Wright, PhD (NHLBI project officer). Ex officio members include Laura Coker, PhD, Aaron Folsom, MD, MPH, Rebecca F. Gottesman, MD, PhD, A. Richey Sharrett, MD, DrPH, Lynne Wagenknecht, DrPH, and Lisa M. Wruck, PhD. Members of the ARIC-NCS Data Analysis Committee (drafted and critically revised all analysis plans) include A. Richey Sharrett, MD, DrPH (chair), Karen Bandeen-Roche, PhD (senior statistician), Andrea L. C. Schneider, PhD, Josef Coresh, MD, PhD, Jennifer Deal, PhD, Rebecca F. Gottesman, MD, PhD, Michael Griswold, PhD, Alden Gross, PhD, Thomas H. Mosley, PhD, Melinda C. Power, ScD, Andreea Rawlings, MS, Lisa M. Wruck, PhD, and Shoshana Ballew, PhD (epidemiologist coordinator). Members of the ARIC-NCS Neurocognitive Committee include Thomas H. Mosley, PhD (chair), Rebecca F. Gottesman, MD, PhD (cochair), Alvaro Alonso, MD, PhD, Laura Coker, PhD, David Couper, PhD, David Knopman, MD, Guy McKhann, MD, Ola Selnes, PhD, and A. Richey Sharrett, MD, DrPH.
Additional Contributions: We thank the staff and participants of the ARIC Study for their important contributions.